Atossa Therapeutics, Inc. financial data

Symbol
ATOS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10202 5 Th Avenue Ne, Suite 200, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ATOSSA GENETICS INC (to 11/13/2019)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.82K % -41%
Debt-to-equity 5.55 % +71.8%
Return On Equity -29.2 % -6.15%
Return On Assets -27.7 % -3.79%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 126M shares -0.02%
Common Stock, Shares, Outstanding 125M shares -0.95%
Entity Public Float 160M USD +15.6%
Common Stock, Value, Issued 22.9M USD +0.36%
Weighted Average Number of Shares Outstanding, Basic 126M shares -0.7%
Weighted Average Number of Shares Outstanding, Diluted 126M shares -0.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.4M USD +0.33%
General and Administrative Expense 13.1M USD -5.24%
Operating Income (Loss) -30.6M USD +2.14%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.9M USD +18%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -25.9M USD +18%
Earnings Per Share, Basic -0.21 USD/shares +16%
Earnings Per Share, Diluted -0.05 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79.5M USD -20%
Other Assets, Current 7K USD -96.5%
Assets, Current 81.7M USD -22.9%
Operating Lease, Right-of-Use Asset 0 USD
Other Assets, Noncurrent 2.43M USD +279%
Assets 85.9M USD -20.8%
Accounts Payable, Current 1.06M USD -10.1%
Employee-related Liabilities, Current 939K USD -35.5%
Accrued Liabilities, Current 1.91M USD +137%
Liabilities, Current 5.7M USD +63.8%
Liabilities 5.7M USD +63.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -54K USD
Retained Earnings (Accumulated Deficit) -198M USD -15%
Stockholders' Equity Attributable to Parent 80.2M USD -23.6%
Liabilities and Equity 85.9M USD -20.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.7M USD +33.1%
Net Cash Provided by (Used in) Financing Activities 204K USD
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 350M shares +100%
Common Stock, Shares, Issued 126M shares -0.59%
Common Stock, Par or Stated Value Per Share 0.18 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.5M USD +35.9%
Deferred Tax Assets, Valuation Allowance 24.6M USD +27.5%
Deferred Tax Assets, Gross 24.7M USD +28%
Operating Lease, Liability 0 USD
Depreciation 5K USD +66.7%
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.23M USD +22.8%
Deferred Tax Assets, Operating Loss Carryforwards 13.3M USD +15.2%
Preferred Stock, Shares Issued 582 shares -41.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 257M USD
Preferred Stock, Shares Outstanding 582 shares -41.8%
Depreciation, Depletion and Amortization 3K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 94K USD +9300%
Share-based Payment Arrangement, Expense 2.21M USD -65.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%